GlassScriptPhysician profile
Christine Snyder
NPI 1942302708
$1,643.21
in general payments reported to CMS, 2019-2025
30 companies · $426 in 2025
The $426 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $184 · 2021: $319 · 2022: $78.81 · 2023: $227 · 2024: $131 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $309.41 | 2019-2025 | Orilissa, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $193.40 | 2019-2025 | |
| Hologic Sales and Service, LLC | $187.51 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $131.69 | 2019-2025 | Veozah |
| Aspira Women'S Health INC | $85.71 | 2021 | |
| Exeltis, USA INC. | $82.84 | 2021-2025 | Slynd |
| Pfizer INC. | $61.47 | 2020-2023 | |
| Baxter Healthcare | $51.59 | 2020-2024 | Perclot |
| Teleflex LLC | $46.71 | 2025 | Quikclot |
| Sumitomo Pharma America, INC. | $38.66 | 2023-2025 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $37.92 | 2020-2021 | |
| Lsi Solutions INC | $34.36 | 2025 | Fornisee |
| Myovant Sciences INC. | $33.06 | 2021 | |
| Exact Sciences Corporation | $32.13 | 2025 | The Cologuard Plus Collection Kit |
| Coopersurgical, INC. | $31.90 | 2021-2023 | Paragard T 380a |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $31.84 | 2019-2021 | |
| Organon LLC | $31.05 | 2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $23.28 | 2025 | Gardasil 9 |
| C. R. Bard, INC. & Subsidiaries | $22.76 | 2024 | Bd Onclarity |
| Daiichi Sankyo INC. | $18.88 | 2020 | |
| Roche Diagnostics Corporation | $18.29 | 2021 | |
| Mayne Pharma Commercial LLC | $18.18 | 2023 | |
| Avion Pharmaceuticals | $18.12 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.07 | 2021 | |
| Sage Therapeutics, LLC | $18.05 | 2025 | Zurzuvae |
| Allergan, INC. | $14.75 | 2019 | |
| Medtronic, INC. | $14.40 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.36 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.52 | 2019 | |
| Ethicon US, LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.